Blau综合征相关葡萄膜炎:一项国际前瞻性干预性病例系列的初步结果
该多中心前瞻性干预性病例系列纳入全球25个中心的50例Blau综合征患者,基线时38例(78%)患葡萄膜炎,以双眼受累(37例,97%)和全葡萄膜炎(38眼,51%)为主,基线时30眼(40%)存在活动性前房炎症,尽管持续接受全身和局部免疫调节治疗,仍导致严重眼部病变。
要点
- Blau葡萄膜炎以进行性全葡萄膜炎伴多灶性脉络膜炎为特征,可导致严重眼部病变。
- 基线时38例(78%)患葡萄膜炎,其中双眼受累37例(97%),全葡萄膜炎38眼(51%)。
- 尽管持续接受全身和局部免疫调节治疗,眼部病变仍严重,需密切眼科监测并寻找更有效疗法。
核心结论
- Blau葡萄膜炎以进行性全葡萄膜炎伴多灶性脉络膜炎为特征,尽管持续接受全身和局部免疫调节治疗,仍导致严重眼部病变。
- Blau葡萄膜炎的发生频率和严重程度突出表明需要密切眼科监测以及寻找更有效的治疗。
研究设计与样本
- 多中心、前瞻性干预性病例系列,纳入全球25个中心的50例患者,收集基线数据及入组结束时随访1年、2年或3年的患者随访数据。
- 眼科数据在基线和每年访视时通过标准化收集表采集。
主要发现
- 眼部疾病发病年龄中位数为60个月,基线时眼部疾病病程为145个月。
- 基线时38例(78%)患葡萄膜炎,其中双眼受累37例(97%);8例(21%)有中度至重度视力损害。
- 全葡萄膜炎见于38眼(51%),特征性多灶性脉络膜浸润见于29眼(39%);视盘苍白9眼(12%)和视盘周围结节9眼(12%)是最常见的视神经受累体征。
- 基线时活动性前房炎症见于30眼(40%),随访1年、2年、3年时分别见于16眼(34%)、17眼(57%)、11眼(61%)。
- 全葡萄膜炎与较长疾病病程相关;基线时56眼(75%)使用局部糖皮质激素,26例患者(68%)接受全身糖皮质激素和免疫调节治疗联合方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Provide baseline and preliminary follow-up results in a 5-year longitudinal study of Blau syndrome. DESIGN: Multicenter, prospective interventional case series. METHODS: Baseline data from 50 patients from 25 centers worldwide, and follow-up data for patients followed 1, 2, or 3 years at the end of study enrollment. Ophthalmic data were collected at baseline and yearly visits by means of a standardized collection form. RESULTS: Median age at onset of eye disease was 60 months and duration of eye disease at baseline 145 months. At baseline 38 patients (78%) had uveitis, which was bilateral in 37 (97%). Eight patients (21%) had moderate to severe visual impairment. Panuveitis was found in 38 eyes (51%), with characteristic multifocal choroidal infiltrates in 29 eyes (39%). Optic disc pallor in 9 eyes (12%) and peripapillary nodules in 9 eyes (12%) were the commonest signs of optic nerve involvement. Active anterior chamber inflammation was noted in 30 eyes (40%) at baseline and in 16 (34%), 17 (57%), and 11 (61%) eyes at 1, 2, and 3 years, respectively. Panuveitis was associated with longer disease duration. At baseline, 56 eyes (75%) were on topical corticosteroids. Twenty-six patients (68%) received a combination of systemic corticosteroids and immunomodulatory therapy. CONCLUSIONS: Blau uveitis is characterized by progressive panuveitis with multifocal choroiditis, resulting in severe ocular morbidity despite continuous systemic and local immunomodulatory therapy. The frequency and severity of Blau uveitis highlight the need for close ophthalmologic surveillance as well as a search for more effective therapies.
引用
- Sarens IL, Casteels I, Anton J, et al. Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. Am J Ophthalmol. 2017. PMID: 28887115. doi:10.1016/j.ajo.2017.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。